Intech Investment Management LLC Sells 20,478 Shares of Indivior PLC $INDV

Intech Investment Management LLC trimmed its position in Indivior PLC (NASDAQ:INDV) by 33.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 41,175 shares of the company’s stock after selling 20,478 shares during the period. Intech Investment Management LLC’s holdings in Indivior were worth $993,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the business. CWM LLC bought a new stake in Indivior during the 3rd quarter worth about $25,000. Raymond James Financial Inc. acquired a new stake in shares of Indivior in the second quarter valued at about $26,000. Plato Investment Management Ltd bought a new stake in Indivior during the third quarter worth about $52,000. Blue Trust Inc. bought a new stake in Indivior during the third quarter worth about $99,000. Finally, Amalgamated Bank acquired a new position in Indivior during the second quarter valued at approximately $61,000. Institutional investors own 60.33% of the company’s stock.

Indivior Stock Up 0.7%

NASDAQ:INDV opened at $32.27 on Monday. Indivior PLC has a 12-month low of $8.64 and a 12-month high of $38.00. The firm has a market capitalization of $4.04 billion, a price-to-earnings ratio of 19.68 and a beta of 0.83. The stock’s 50 day moving average price is $34.11 and its two-hundred day moving average price is $30.39.

Indivior (NASDAQ:INDV) last issued its earnings results on Thursday, February 26th. The company reported $0.82 EPS for the quarter, topping the consensus estimate of $0.65 by $0.17. The company had revenue of $358.00 million during the quarter, compared to the consensus estimate of $305.62 million. Indivior had a negative return on equity of 148.76% and a net margin of 16.85%. Equities research analysts expect that Indivior PLC will post 1.22 EPS for the current year.

Insider Buying and Selling at Indivior

In related news, Director Barbara Ryan purchased 775 shares of the stock in a transaction on Monday, January 5th. The shares were purchased at an average cost of $35.39 per share, with a total value of $27,427.25. Following the acquisition, the director directly owned 1,963 shares in the company, valued at $69,470.57. The trade was a 65.24% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Keith Humphreys acquired 775 shares of Indivior stock in a transaction dated Monday, January 5th. The shares were purchased at an average price of $35.39 per share, with a total value of $27,427.25. Following the acquisition, the director owned 5,802 shares of the company’s stock, valued at approximately $205,332.78. This trade represents a 15.42% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have acquired 4,871 shares of company stock worth $172,385.

Analysts Set New Price Targets

INDV has been the subject of a number of analyst reports. HC Wainwright raised their price target on Indivior from $35.00 to $48.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Northland Securities set a $50.00 price objective on Indivior in a report on Tuesday, January 20th. Weiss Ratings raised shares of Indivior from a “hold (c)” rating to a “buy (b-)” rating in a research note on Monday, March 2nd. Zacks Research downgraded shares of Indivior from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 13th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $36.00 price target on shares of Indivior in a research report on Wednesday, December 3rd. Six equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, Indivior currently has a consensus rating of “Moderate Buy” and an average price target of $39.33.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.